Traffic Lights - Latest Updates

Last updated: 20/04/2018

Other updates on this site
Drug Name Classification Clinical Indication Comments
ACAMPROSATE (UPDATED) Amber Simple Alcohol dependence
ADALIMUMAB (NEW) Red Plaque psoriasis in children

In line with NICE TA 455

ADALIMUMAB (NEW) Red Non-infectious uveitis

In line with NICE TA 460

AFLIBERCEPT (Eylea®) (UPDATED) Red Wet age related macular degeneration. Diabetic macular oedema. Macular oedema due to central retinal vein occlusion and branch retinal vein occlusion. Choroidal neovascularisation.

In line with NICE TA294, NICE TA346, NICE TA305, NICE TA409, NICE TA486

ALIMEMAZINE (UPDATED) Black Various

Current patients should be discussed with the prescribing specialist and not have treatment stopped abruptly without appropriate review.

ALPROSTADIL uretheral sticks and injections (NEW) Green Erectile dysfunction

Not prescribable under the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIB of the Drug Tariff. The prescription must be endorsed ‘SLS’.

Maximum 4 doses per month to be prescribed.

APIXABAN (UPDATED) Amber Simple Treatment and secondary prevention of DVT and PE

In line with NICE TA 341

APREMILAST (Otezla®) (UPDATED) Red Psoriatic arthritis

In line with NICE TA 433

BASILIXIMAB (Simulect®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

BELATACEPT (Nulojix®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

BIOSIMILAR TRASTUZUMAB (Ontruzant®) (NEW) Black for HER2 positive metastatic and early stage breast cancer, HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
BOTULINUM A TOXIN (Xeomin®) Red As per licence
BUDESONIDE 64mcg NASAL SPRAY (Benacort®) (NEW) Black
BUDESONIDE and FORMETEROL (Fobumix®) Easyhaler (NEW) Green Asthma
CALCIPOTRIOL/BETAMETHASONE CUTANEOUS FOAM (Enstilar®) (UPDATED) Green Psoriasis vulgaris

Management of Psoriasis in Primary Care

CARIPRAZINE (NEW) Black Schizophrenia
CERTOLIZUMAB PEGOL (NEW) Red Psoriatic arthritis

In line with NICE TA 445

CIPROFLOXACIN 2mg/ml ear drops (Cetraxal ®) (NEW) Black Acute otitis media

Not yet reviewed

CLADRIBINE (NEW) Red Relapsing-remitting multiple sclerosis

In line with NICE TA 493

COLLAGENASE CLOSTRIDIUM HISTOLYCUM (NEW) Red Dupuytrens

In Line with NICE TA 459

CORNEAL EPITHELIAL CELLS (Ex vivo expanded autologous human) containing stem cells (Holoclar®) (NEW) Red Moderate-severe limbal stem cell deficiency after eye burns

In line with NICE TA 467

DACLIZUMAB (UPDATED) Red Relapsing forms of multiple sclerosis

In line with NICE TA 441

DIMETHYL FUMARATE (NEW) Red Moderate to severe plaque psoriasis

In line with NICE TA 475

DUPILUMAB (Dupixent®) (NEW) Black
ELUXADOLINE (Truberzi®) (NEW) Red Irritable bowel syndrome with diarrhoea

In line with NICE TA 471

EMICIZUMAB (Hemlibra®) (NEW) Black For prophylaxis of bleeding episodes
ENOXAPARIN BECAT prefilled syringes (NEW) Black Parenteral anticoagulant
ETANERCEPT (NEW) Red Plaque psoriasis in children

In line with NICE TA 455

EVEROLIMUS (Certican®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

FIBRINOGEN (Riastap®) (NEW) Red Treatment of severe bleeding in acquired hypofibrinogenemia resulting from operative interventions, in particular after cardiac surgery
FLUTICASONE / AZELASTINE NASAL SPRAY (Dymista®) (UPDATED) Green Rhinitis

To be used in line with the Allergic Rhinitis Pathway

GLECAPREVIR-PIBRENTASVIR (Maviret®) (NEW) Red Hepatitis C

In line with NICE TA 499

GLUCODRATE® (NEW) Amber Simple High Output Stoma (HOS)
GOLIMUMAB (NEW) Red Non-radiographic axial spondyloarthritis

In line with NICE TA 497

GUSELKUMAB (Tremfya®) (NEW) Black Moderate to severe plaque psoriasis in adults
HISTIDINE TRYTOPHAN KETOGLUTARATE MANITOL (Custodiol®) (NEW) Red For myocardial protection in complex cardiac surgery. For organ preservation in transplant surgery
HYDROCORTISONE (Alkindi®)(Granules in capsules for opening) (NEW) Black Adrenal insufficiency in infants
INSULIN GLARGINE (Toujeo® 300units per ml) (UPDATED) Green Conditional Diabetes mellitus in adults

UKMI – Product Safety Assessment Report
MUST BE PRESCRIBED BY BRAND NAME

INTERFERON GAMMA (Immukin®) (NEW) Red For mycobacterial infections and pulmonary and miliary
LEVETIRACETAM (NEW) Green Conditional Palliative care in line with guidance

Conditional on recommendation from palliative care team.
Palliative Care Prescribing

MYCOPHENOLATE (UPDATED) Amber Full SCA Immunosuppression following renal transplantation

Exception agreed to red status: Full shared care to allow GPs to continue supplying to historical patients still on shared care where appropriate for patient and the GP agrees.

Full SCA

MYCOPHENOLATE (NEW) Red Immunosuppression following renal transplantation
NALOXONE (NEW) Green Conditional Palliative care in line with guidance.

Conditional on recommendation from palliative care team.
Palliative Care Prescribing

NALTREXONE / BUPROPION M/R (Mysimba®) (NEW) Black Managing obesity

NICE TA 494 not supported for managing obesity in adults

OCRELIZUMAB (Ocrevus®) (NEW) Black
PATIROMER (Veltassa®) (NEW) Black
PIRFENIDONE (Esbriet®) (UPDATED) Red For Idiopathic pulmonary fibrosis

In line with NICE TA 504 (Replaces NICE TA 282)

QUETIAPINE (NEW) Green Conditional Palliative care in line with guidance.

Conditional on recommendation from palliative care team.
Palliative Care Prescribing

RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN (Thymoglobuline®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

RESLIZUMAB (NEW) Red Severe Eosinophilic Asthma

In line with NICE TA 479

RIVAROXABAN (UPDATED) Amber Simple Treatment and secondary prevention of DVT and PE

In line with  NICE TA 261  or  NICE TA 287

ROFLUMILAST (UPDATED) Amber Simple COPD

In line with NICE TA 461

SARILUMAB (NEW) Red Moderate to Severe Rheumatoid Arthritis

In line with NICE TA 485

SIROLIMUS (NEW) Red Immunosuppression post renal transplant
SIROLIMUS (UPDATED) Amber Full SCA Immunosuppression post renal transplant

Exception agreed to red status: Full shared care to allow GPs to continue supplying to historical patients still on shared care where appropriate for patient and the GP agrees. Full SCA

SOFOSBUVIR–VELPATASVIR-VOXILAPREVIR (Vosevi®) (NEW) Red For Chronic hepatitis C

IMPLEMENTATION from 21st May 2018
In line with NICE TA 504

TACROLIMUS capsules (Adoport®, Prograf® or Modigraf®) (UPDATED) Amber Full SCA Immunosuppression post renal transplant - prescribe by brand name only as different brands are not interchangeable

Exception agreed to red status: Full shared care to allow GPs to continue supplying to historical patients still on shared care where appropriate for patient and the GP agrees.
Full SCA

TACROLIMUS capsules (Adoport®, Prograf® or Modigraf®) (NEW) Red Immunosuppression post renal transplant - prescribe by brand name only as different brands are not interchangeable
TACROLIMUS SR (Envarsus®) (NEW) Red Prophylaxis of transplant rejection in adult kidney transplants
TIVOZANIB (Fotivda®) (NEW) Black Advanced renal cell carcinoma

Not yet reviewed

TOFACITINIB (NEW) Red Moderate to Severe Rheumatoid Arthritis

In line with NICE TA 480

TRAMADOL HYDROCHLORIDE / DEXKETOPROFEN (Skudexa®) (NEW) Black Pain
ULIPRISTAL ACETATE (Esmya®) (UPDATED) Amber Simple Pre-operative treatment of uterine fibroids.
Review appropriateness of treatment after 3/12

Existing patients only

ULIPRISTAL ACETATE (Esmya®) (UPDATED) Black Uterine fibroids.

New patients only.
MHRA healthcare professional letter

 

USTEKINUMAB (NEW) Red Plaque psoriasis in children

In line with NICE TA 455

VALPROATE SEMISODIUM (Depakote®) (NEW) Amber Simple Mania in bipolar disorder

Other Updates on this Website

Recent documents from LMSG and TAS

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more